You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

R/R Non-Hodgkin's Lymphomas

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Relapsed Chronic Lymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia, Diffuse Large B Cell Lymphoma Trial in United

Recruiting
  • Relapsed Chronic Lymphocytic Leukemia
  • +4 more
  • Phoenix, Arizona
  • +7 more
Apr 28, 2022

Relapsed/Refractory Non-Hodgkin Lymphoma Trial in Duarte, Amsterdam (BMS-986458, Rituximab)

Not yet recruiting
  • Relapsed/Refractory Non-Hodgkin Lymphoma
  • Duarte, California
  • +1 more
Oct 13, 2023

Refractory Aggressive B-cell Lymphomas, Refractory B-Cell Non-Hodgkin Lymphoma, Aggressive B-cell NHL Trial in Boston

Not yet recruiting
  • Refractory Aggressive B-cell Lymphomas
  • +12 more
  • Boston, Massachusetts
  • +1 more
Oct 13, 2022

Lymphomas Non-Hodgkin's B-Cell Trial in Ballarat, Box Hill, Heidelberg (Avelumab)

Active, not recruiting
  • Lymphomas Non-Hodgkin's B-Cell
  • Ballarat, Victoria, Australia
  • +2 more
Jan 30, 2023

B-Cell Lymphoma, Non-Hodgkin Lymphoma Trial in Worldwide (Glofitamab, Obinutuzumab (G), Rituximab (R))

Active, not recruiting
  • B-Cell Lymphoma
  • Non-Hodgkin Lymphoma
  • Birmingham, Alabama
  • +23 more
Dec 2, 2022

Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell Trial in China (Chidamide, Cladribine, Gemcitabine)

Recruiting
  • Lymphoma, Large B-Cell, Diffuse
  • Lymphoma, T-Cell
  • Deyang, Deyang, China
  • +10 more
Jul 21, 2022

Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Follicular Lymphoma, Recurrent Indolent Adult Non-Hodgkin Lymphoma Trial in

Suspended
  • Recurrent B-Cell Non-Hodgkin Lymphoma
  • +7 more
  • Philadelphia, Pennsylvania
    Sidney Kimmel Cancer Center at Thomas Jefferson University
Jan 20, 2023

Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma Trial in Atlanta (drug, biological,

Recruiting
  • Grade 1 Follicular Lymphoma
  • +7 more
  • Atlanta, Georgia
    Emory University Hospital/Winship Cancer Institute
Dec 7, 2021

Recurrent Anaplastic Large Cell Lymphoma, Recurrent Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Recurrent Primary Cutaneous

Recruiting
  • Recurrent Anaplastic Large Cell Lymphoma
  • +8 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Apr 6, 2022

Lymphoma, Non-Hodgkin Trial in Worldwide (CC-99282, Rituximab, Obinutuzumab)

Recruiting
  • Lymphoma, Non-Hodgkin
  • Los Angeles, California
  • +86 more
Jan 23, 2023

Aggressive B Cell Non-Hodgkin Lymphomas at High Risk for R-CHOP-21-induced Neutropenia Trial in Germany, Italy, Spain

Completed
  • Aggressive B Cell Non-Hodgkin Lymphomas at High Risk for R-CHOP-21-induced Neutropenia
  • Aurich, Germany
  • +59 more
Jun 6, 2022

Advanced Solid Tumors, B-cell Non-Hodgkin Lymphomas Trial (ATG-031)

Not yet recruiting
  • Advanced Solid Tumors
  • B-cell Non-Hodgkin Lymphomas
  • (no location specified)
Aug 31, 2023

Aggressive Non-Hodgkin Lymphoma Trial in Italy (Prednisone, Vinorelbine, Etoposide)

Completed
  • Aggressive Non-Hodgkin Lymphoma
  • Brescia, Italy
  • +9 more
Dec 17, 2021

Non-Hodgkin's Lymphoma (NHL), Peripheral T Cell Lymphoma (PTCL) Trial in Tianjin (Ex-vivo expanded allogeneic ?dT cells)

Recruiting
  • Non-Hodgkin's Lymphoma (NHL)
  • Peripheral T Cell Lymphoma (PTCL)
  • Ex-vivo expanded allogeneic γδT cells
  • Tianjin, Tianjin, China
    Institute of Hematology & Blood Disease Hospital
Jan 5, 2021

Hodgkin Lymphoma, DLBCL Trial run by the NCI (campath, Rituximab, EPOCH)

Completed
Has Results
  • Hodgkin Lymphoma
  • Diffuse Large B-Cell Lymphoma
  • Campath
  • +2 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center, 9000 Rockville Pi
Sep 11, 2022

Leukemia, Acute Lymphoblastic, Lymphoma, Non-Hodgkin Trial in Ribeirao Preto (CART-19)

Not yet recruiting
  • Leukemia, Acute Lymphoblastic
  • Lymphoma, Non-Hodgkin
  • CART-19
  • Ribeirao Preto, Sao Paulo, Brazil
    Ribeirao Preto School of Medicine, University of Sao Paulo
Oct 23, 2023

Advanced Malignancies Trial in Beijing (1A46 Drug Substance)

Not yet recruiting
  • Advanced Malignancies
  • 1A46 Drug Substance
  • Beijing, Beijing, China
    Beijing Cancer Hospital
Aug 4, 2023

Relapsed or Refractory Non-Hodgkin's Lymphoma Trial in China (AXT-1003)

Not yet recruiting
  • Relapsed or Refractory Non-Hodgkin's Lymphoma
  • Beijing, China
  • +3 more
Jul 20, 2023

Lymphoma, Non-Hodgkin, Diffuse Large B Cell Lymphoma Trial in Tianjin (CD19-targeted Chimeric Antigen Receptor(CAR) T Cells)

Recruiting
  • Lymphoma, Non-Hodgkin
  • Diffuse Large B Cell Lymphoma
  • CD19-targeted Chimeric Antigen Receptor(CAR) T Cells
  • Tianjin, Tianjin, China
    Tianjin Cancer Hospital
Nov 19, 2023

NHL, NHL, Relapsed, Adult Trial in United States (CLN-978)

Recruiting
  • NHL
  • NHL, Relapsed, Adult
  • Birmingham, Alabama
  • +4 more
May 31, 2023

Non-Hodgkin's Lymphoma, Ann Arbor Stage II Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Ann Arbor

Recruiting
  • Non-Hodgkin's Lymphoma
  • +18 more
  • Philadelphia, Pennsylvania
    Sidney Kimmel Cancer Center at Thomas Jefferson University
Mar 11, 2021

Non-Hodgkin's Lymphoma, Relapsed, Chronic Lymphoid Leukemia in Relapse, Non-Hodgkin's Lymphoma Refractory Trial in United States

Completed
Has Results
  • Non-Hodgkin's Lymphoma, Relapsed
  • +8 more
  • PBCAR20A
  • +2 more
  • Duarte, California
  • +4 more
Jan 4, 2023

Non Hodgkin's Lymphoma Trial in Beijing (TRAC and Power3 Genes Knock-out Allogeneic CD19-targeting CAR-T cell (ATHENA CAR-T),

Not yet recruiting
  • Non Hodgkin's Lymphoma
  • TRAC and Power3 Genes Knock-out Allogeneic CD19-targeting CAR-T cell (ATHENA CAR-T)
  • +2 more
  • Beijing, China
  • +2 more
Aug 23, 2023

Aggressive Non-Hodgkin Lymphoma, ALK-Positive Large B-Cell Lymphoma, B-Cell Lymphoma, Unclassifiable, With Features Intermediate

Recruiting
  • Aggressive Non-Hodgkin Lymphoma
  • +8 more
  • Polatuzumab Vedotin
  • +6 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Jan 26, 2023

Non Hodgkin's Lymphoma Trial in Beijing (Allogenic CD19-CAR-?dT cell, Fludarabine, Cyclophosphamide)

Recruiting
  • Non Hodgkin's Lymphoma
  • Allogenic CD19-CAR-γδT cell
  • +2 more
  • Beijing, Beijing, China
  • +1 more
Jan 31, 2023